Langerhans cell histiocytosis (LCH)
Clinical trials for Langerhans cell histiocytosis (LCH) explained in plain language.
Never miss a new study
Get alerted when new Langerhans cell histiocytosis (LCH) trials appear
Sign up with your email to follow new studies for Langerhans cell histiocytosis (LCH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise for rare childhood diseases
Disease control Recruiting nowThis phase 2 trial is testing the drug mirdametinib in 40 people aged 2 and older with Langerhans cell histiocytosis or similar disorders. The goal is to see if this oral medication works better and has fewer side effects than current treatments. Participants take the drug twice …
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Could existing cancer drugs tackle rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New targeted drug combo aims to curb relapse in kids with rare immune disorder
Disease control Recruiting nowThis study tests whether adding the targeted drug luvometinib to standard chemotherapy improves outcomes for children with multisystem Langerhans cell histiocytosis (LCH), a rare immune cell disorder. About 120 children aged 0-18 with newly diagnosed, untreated LCH will be random…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill could spare kids with rare bone disease from chemo
Disease control Recruiting nowThis study tests a new daily oral drug called luvometinib in children aged 0-18 with Langerhans cell histiocytosis (LCH) that affects certain bones. LCH is a rare condition where immune cells build up and can cause bone damage. The drug targets a faulty cell signal found in nearl…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC